A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders

Journal of Rheumatology

Volumn 41, Issue 2, 2014, Pages 293-299

  Yamakawa, Noriyuki ^a   Fujimoto, Masakazu ^a   Kawabata, Daisuke ^a   Terao, Chikashi ^a   Nishikori, Momoko ^b   Nakashima, Ran ^a   Imura, Yoshitaka ^a   Yukawa, Naoichiro ^a   Yoshifuji, Hajime ^a   Ohmura, Koichiro ^a   Fujii, Takao ^a   Kitano, Toshiyuki ^b   Kondo, Tadakazu ^b   Yurugi, Kimiko ^c   Miura, Yasuo ^c   Maekawa, Taira ^c   Saji, Hiroh ^d   Takaori Kondo, Akifumi ^b   Matsuda, Fumihiko ^a   Haga, Hironori ^a   Mimori, Tsuneyo ^a,b   more..

^a Center for Genomic Medicine   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

^d Japanese Red Cross Kanto Koshinetsu Block Blood Center   (Japan)

Author keywords

Hematopoietic system; HLA antigens; Rheumatic diseases; Rheumatoid arthritis; Skin manifestations

Indexed keywords

HEMATOPOIETIC SYSTEM; HLA ANTIGENS; RHEUMATIC DISEASES; RHEUMATOID ARTHRITIS; SKIN MANIFESTATIONS;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HERPESVIRUS 4, HUMAN; HLA ANTIGENS; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; METHOTREXATE; MIDDLE AGED; POLYMYOSITIS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84893612458     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.130270     Document Type: Article

References (26)

1. Gaulard P. Swerdlow SH, Harris NL, Jaffe ES, Sundstrom C. Other iatrogenic immunodeficiency-associated lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al, eds. Tumours of haematopoietic and lymphoid tissues. Pathology & genetics. World Health Organization classification of tumours. 4th ed. Lyon: IARC Press; 2008:350-1.
2. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22.
3. Rath T, Rubbert A. Drug combinations with methotrexate to treat rheumatoid arthritis. Clin Exp Rheumatol 2010;5 Suppl 61:S52-7.
4. Harris NL, Swerdlow SH. Methotrexate-associated lymphoproliferative disorders. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Tumours of haematopoietic and lymphoid tissues. Pathology & genetics. World Health Organization classification of tumours. 3rd ed. Lyon: IARC Press; 2001:270-1.
5. Feng WH, Cohen JI, Fischer S, Li L, Sneller M, Goldbach-Mansky R, et al. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst 2004;96:1691-702.
6. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004;4:757-68.
7. Dojcinov SD, Venkataraman G, Raffeld M, Pittaluga S, Jaffe ES. EBV positive mucocutaneous ulcer - a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol 2010;34:405-17.
8. Oyama T, Ichimura K, Suzuki R, Suzumiya J, Ohshima K, Yatabe Y, et al. Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol 2003;27:16-26.
9. Ohmura K, Terao C, Maruya E, Katayama M, Matoba K, Shimada K, et al. Anti-citrullinated peptide antibody-negative RA is a genetically distinct subset: a definitive study using only bone-erosive ACPA-negative rheumatoid arthritis. Rheumatology 2010;49:2298-304.
10. Hashizume H, Uchiyama I, Kawamura T, Suda T, Takigawa M, Tokura Y. Epstein-Barr virus-positive mucocutaneous ulcers as a manifestation of methotrexate-associated B-cell lymphoproliferative disorders. Acta Derm Venereol 2012;92:276-7.
11. Curry JL, Prieto VG, Jones DM, Vega F, Duvic M, Diwan AH. Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/Sezary syndrome. J Cutan Pathol 2011;38:295-7.
12. Shimura C, Satoh T, Takayama K, Yokozeki H. Methotrexate-related lymphoproliferative disorder with extensive vascular involvement in a patient with rheumatoid arthritis. J Am Acad Dermatol 2009;61:126-9.
13. Pastor-Nieto MA, Kilmurray LG, Lopez-Chumillas A, O'Valle F, Garcia-Del Moral R, Puig AM, et al. Methotrexate-associated lymphoproliferative disorder presenting as oral ulcers in a patient with rheumatoid arthritis [in Spanish]. Actas Dermosifiliogr 2009;100:142-6.
14. Uneda S, Sonoki T, Nakamura Y, Matsuoka H, Nakakuma H. Rapid vanishing of tumors by withdrawal of methotrexate in Epstein-Barr virus-related B cell lymphoproliferative disorder. Intern Med 2008;47:1445-6.
15. Tanaka A, Shigematsu H, Kojima M, Sakashita H, Kusama K. Methotrexate-associated lymphoproliferative disorder arising in a patient with adult Still's disease. J Oral Maxillofac Surg 2008;66:1492-5.
16. Maruani A, Wierzbicka E, Machet MC, Abdallah-Lotf M, de Muret A, Machet L. Reversal of multifocal cutaneous lymphoproliferative disease associated with Epstein-Barr virus after withdrawal of methotrexate therapy for rheumatoid arthritis. J Am Acad Dermatol 2007;5 Suppl:S69-71.
17. Clarke LE, Junkins-Hopkins J, Seykora JT, Adler DJ, Elenitsas R. Methotrexate-associated lymphoproliferative disorder in a patient with rheumatoid arthritis presenting in the skin. J Am Acad Dermatol 2007;56:686-90.
18. Dojcinov SD, Venkataraman G, Pittaluga S, Wlodarska I, Schrager JA, Raffeld M, et al. Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood 2011;117:4726-35.
19. Oyama T, Yamamoto K, Asano N, Oshiro A, Suzuki R, Kagami Y, et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res 2007;13:5124-32.
20. Shimoyama Y, Yamamoto K, Asano N, Oyama T, Kinoshita T, Nakamura S. Age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorders: special references to lymphomas surrounding this newly recognized clinicopathologic disease. Cancer Sci 2008;99:1085-91.
21. Miyazaki T, Fujimaki K, Shirasugi Y, Yoshiba F, Ohsaka M, Miyazaki K, et al. Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol 2007;82:1106-9.
22. Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation 2003;76:984-8.
23. Asano N, Yamamoto K, Tamaru J, Oyama T, Ishida F, Ohshima K, et al. Age-related Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders: comparison with EBV-positive classic Hodgkin lymphoma in elderly patients. Blood 2009;113:2629-36.
24. Hoshida Y, Tomita Y, Zhiming D, Yamauchi A, Nakatsuka S, Kurasono Y, et al. Lymphoproliferative disorders in autoimmune diseases in Japan: analysis of clinicopathological features and Epstein-Barr virus infection. Int J Cancer 2004;108:443-9.
25. Masucci MG. Epstein-Barr virus oncogenesis and the ubiquitin-proteasome system. Oncogene 2004;23:2107-15.
26. Teruya-Feldstein J, Jaffe ES, Burd PR, Kanegane H, Kingma DW, Wilson WH, et al. The role of Mig, the monokine induced by interferon-gamma, and IP-10, the interferon-gamma-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease. Blood 1997;90:4099-105.